STAT Plus: Karyopharm hides higher death rate tied to blood cancer drug, dimming approval hopes
The higher death rate was not revealed until the FDA disclosed it as part of a skeptical review that could stop the drug from reaching the market.
Suscribirse a:
Enviar comentarios (Atom)
No hay comentarios:
Publicar un comentario